ARCA Biopharma Inc

Type: Company
Name: ARCA Biopharma Inc
First reported 7 hours ago - Updated 7 hours ago - 1 reports

ARCA screens first patient in Phase IIB/III atrial fibrillation trial

ARCA biopharma, Inc., a developer of genetically targeted therapies for cardiovascular diseases, has screened first patient in GENETIC-AF, its Phase IIB/III adaptive design clinical trial to evaluate Gencaro as a treatment for the prevention of atrial ... [Published Individual.com - 7 hours ago]
First reported Apr 22 2014 - Updated Apr 22 2014 - 2 reports

ARCA biopharma to Present at the Growth Capital Expo 2014

WESTMINSTER, Colo.--(BUSINESS WIRE)-- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that its Chief Financial Officer, Patrick Wheeler, will present ... [Published Nasdaq - Apr 22 2014]
First reported Apr 22 2014 - Updated Apr 22 2014 - 2 reports

ARCA biopharma Reports Screening of 1st Patient in Phase 2B/3 Clinical Trial Evaluating Gencaro in Atrial Fibrillation

ARCA biopharma, Inc. , a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 adaptive design clinical trial.According ... [Published HispanicBusiness.com - Apr 22 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 3 reports

ARCA biopharma Announces Screening of First Patient in Phase 2B/3 Clinical Trial Evaluating Gencaro in Atrial Fibrillation

WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA announces the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 clinical trial that will evaluate Gencaro as a potential genetically targeted treatment for A-fib. ... [Published Business Wire Photo/Multimedia News - Apr 17 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 2 reports

ARCA biopharma Files Shelf Registration Statement

WESTMINSTER, Colo.--( BUSINESS WIRE )--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical companydeveloping genetically-targeted therapies for cardiovascular diseases,today announced that it has filed a universal shelf registrationstatement with ... [Published Business Wire - Apr 04 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

Checking In On ARCA Biopharma

By Jason Napodano :On March 20, 2014, ARCA Biopharma ( ABIO ) filed its Form 10-K annual report for the period ending December 31, 2013, providing investors an update on the financial position and business prospects for the company. A quick look at the ... [Published BioPortfolio - Mar 25 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

Checking In On ARCA Biopharma

SummaryThe company's Phase 2b/3 Clinical Trial, GENETIC-AF, should start very soon. ARCA has cash to make it into early 2016. The development strategy for Gencaro makes sense based on our analysis of the previous data. The shares are attractive for ... [Published Seeking Alpha - Mar 25 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 1 reports

Arca Biopharma’s Outperform Rating Reaffirmed at Zacks (ABIO)

Arca Biopharma (NASDAQ:ABIO)Zacks’ analyst wrote, " Heart failure affects over 6.0 million Americans, and contributes to over 3 million hospitalizations and 250,000 deaths per year. ARCA biopharma is developing Gencaro (bucindolol hydrochloride), a pharmacologically ... [Published American Banking News - Mar 21 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 2 reports

ARCA biopharma CEO Michael R. Bristow to Be Interviewed Live Today on Clear Channel Business Talk Radio

Interview Scheduled at 11:05am PDT / 12:05 pm MDT / 2:05pm EDT on the Traders Network Radio Show, Hosted by Michael Yorba ... [Published Marketwire - Breaking News Releases - Mar 19 2014]
Entities: ARCA Biopharma Inc
First reported Feb 12 2014 - Updated Feb 12 2014 - 2 reports

ARCA adds to board of directors

ARCA biopharma has appointed Dan Mitchell to its board of directors. Mitchell is a manager of Sequel Venture Partners , which he founded. Based in Colorado, ARCA is a biopharmaceutical company focused on cardiovascular diseases. PRESS RELEASE WESTMINSTER, ... [Published PE Hub Blog - Feb 12 2014]
First reported Feb 04 2014 - Updated Feb 04 2014 - 1 reports

ARCA biopharma Announces Pricing of $9 Million Public Offering of Common Stock and Warrants

WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has priced its previously announced public offering of ... [Published Business Wire Health News - Feb 04 2014]
First reported Feb 03 2014 - Updated Feb 03 2014 - 1 reports

ARCA biopharma Announces Proposed Public Offering of Common Stock and Warrants

WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it intends to offer and sell common stock and warrants in ... [Published Business Wire Health News - Feb 03 2014]

Quotes

"This is a major milestone for the company and for the development of Gencaro," said Dr Michael R Bristow, President and CEO of ARCA. "We believe we have an opportunity to potentially improve the treatment options for patients at risk for, or living with, atrial fibrillation by addressing an unmet medical need in patients who also have heart failure and/or left ventricular dysfunction. The Gencaro development program, if successful in GENETIC-AF, would also herald a new era of pharmacogenetically developed cardiovascular drugs."
Zacks’ analyst wrote, " Heart failure affects over 6.0 million Americans, and contributes to over 3 million hospitalizations and 250,000 deaths per year. ARCA biopharma is developing Gencaro (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator currently in a Phase 2b/3 pivotal trial for the treatment of atrial fibrillation (AF) in patients with heart failure and/or left ventricular dysfunction (HFREF). We believe the GENETIC-AF trial will initiate in the next few weeks. ARCA is currently sitting on $22.5 million in cash and investments. The current cash balance is sufficient to fund operation through the end of 2015. We see the shares at attractive for long-term investors, and are maintaining our $3.00 price target and Buy’ rating on the stock."
...some challenging times," William U Parfet, former Upjohn president and board member, and great-grandson of company founder W E Upjohn, said Monday. "He had a great smile, a sound presence and warmed every room he entered."
..." Giroux said he has been commanded to "take the investigation any direction it goes involving criminality in the mayor or the mayor's office." ( http://link.reuters.com/nyx56v )

More Content

All (34) | News (21) | Reports (0) | Blogs (11) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
ARCA screens first patient in Phase IIB/III atr... [Published Individual.com - 7 hours ago]
ARCA biopharma to Present at the Growth Capital... [Published Nasdaq - Apr 22 2014]
ARCA biopharma to Present at the Growth Capital... [Published Business Wire Health News - Apr 22 2014]
ARCA biopharma Reports Screening of 1st Patient... [Published HispanicBusiness.com - Apr 22 2014]
Arca Biopharma Screens First Patient in Phase 2... [Published Individual.com - Apr 22 2014]
ARCA biopharma Announces Screening of First Pat... [Published Business Wire Photo/Multimedia News - Apr 17 2014]
ARCA biopharma Announces Screening of First Pat... [Published Business Wire Health News - Apr 17 2014]
ARCA biopharma Announces Screening of First Pat... [Published Business Wire News with Multimedia - Apr 17 2014]
SmallCapNewsRelease.com: China Voice (CHVC.PK) ... [Published Free Press Release - Apr 05 2014]
ARCA biopharma Files Shelf Registration Statement [Published Business Wire - Apr 04 2014]
ARCA biopharma Files Shelf Registration Statement [Published Business Wire Health News - Apr 04 2014]
Acer Appoints Nancy Hu as Chief Financial Officer [Published Directorship - Apr 04 2014]
Checking In On ARCA Biopharma [Published BioPortfolio - Mar 25 2014]
Checking In On ARCA Biopharma [Published Seeking Alpha - Mar 25 2014]
Arca Biopharma’s Outperform Rating Reaffirmed a... [Published American Banking News - Mar 21 2014]
John L. Zabriskie Jr. [Published Aspen Times - Mar 20 2014]
ARCA biopharma CEO Michael R. Bristow to Be Int... [Published Marketwire - Breaking News Releases - Mar 19 2014]
ARCA biopharma : CEO Michael R. Bristow to Be I... [Published 4 Traders - Mar 19 2014]
Former Upjohn Co. Chairman and CEO John Zabrisk... [Published Michigan Live - Mar 17 2014]
Small-Cap Biotech on the Verge of a Breakout: ABIO [Published The Street Latest - Mar 12 2014]
Top Gainers Technical Data: Ocean Power Technol... [Published Financial Services - Mar 12 2014]
4 Biotech Stocks Under $10 Moving Higher [Published The Street Latest - Feb 26 2014]
ARCA adds to board of directors [Published PE Hub Blog - Feb 12 2014]
Dan Mitchell Joins ARCA biopharma Board of Dire... [Published Business Wire Health News - Feb 12 2014]
5 Stocks Insiders Love Right Now [Published The Street Latest - Feb 05 2014]
Top Insider Trades: PSX YRCW CRTX IDIX [Published The Street Latest - Feb 05 2014]
ARCA biopharma Announces Pricing of $9 Million ... [Published Business Wire Health News - Feb 04 2014]
Frontrunning: February 4 [Published Zero Hedge - Feb 04 2014]
ARCA biopharma Announces Proposed Public Offeri... [Published Business Wire Health News - Feb 03 2014]
Stocks Outperformed the Broader Markets: Facebo... [Published Financial Services - Dec 05 2013]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
ARCA biopharma to Present at the Growth Capital... [Published Business Wire Health News - Apr 22 2014]
WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA to present at Growth Capital Expo 2014 investor conference being held April 29 - May 1, 2014. ...
ARCA biopharma Announces Screening of First Pat... [Published Business Wire Photo/Multimedia News - Apr 17 2014]
WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA announces the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 clinical trial that will evaluate Gencaro as a potential genetically targeted treatment for A-fib. ...
ARCA biopharma Announces Screening of First Pat... [Published Business Wire Health News - Apr 17 2014]
WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA announces the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 clinical trial that will evaluate Gencaro as a potential genetically targeted treatment for A-fib. ...
ARCA biopharma Announces Screening of First Pat... [Published Business Wire News with Multimedia - Apr 17 2014]
WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA announces the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 clinical trial that will evaluate Gencaro as a potential genetically targeted treatment for A-fib. ...
ARCA biopharma Files Shelf Registration Statement [Published Business Wire Health News - Apr 04 2014]
WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has filed a universal shelf registration statement with ...
1 2 3

Press Releases

sort by: Date | Relevance
Top Gainers Technical Data: Ocean Power Technol... [Published Financial Services - Mar 12 2014]
Stocks Outperformed the Broader Markets: Facebo... [Published Financial Services - Dec 05 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.